BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Petri MH, Laguna-Fernandez A, Arnardottir H, Wheelock CE, Perretti M, Hansson GK, Bäck M. Aspirin-triggered lipoxin A4 inhibits atherosclerosis progression in apolipoprotein E-/- mice. Br J Pharmacol 2017;174:4043-54. [PMID: 28071789 DOI: 10.1111/bph.13707] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 10.4] [Reference Citation Analysis]
Number Citing Articles
1 Méndez-Barbero N, Gutiérrez-Muñoz C, Blázquez-Serra R, Martín-Ventura JL, Blanco-Colio LM. Annexins: Involvement in cholesterol homeostasis, inflammatory response and atherosclerosis. Clin Investig Arterioscler 2021;33:206-16. [PMID: 33622609 DOI: 10.1016/j.arteri.2020.12.010] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Bäck M, Ketelhuth D, Malin S, Olofsson P, Paulsson-berne G, Yan Z, Hansson G. Immune-Mediated Mechanisms of Atherosclerosis. Encyclopedia of Cardiovascular Research and Medicine. Elsevier; 2018. pp. 68-76. [DOI: 10.1016/b978-0-12-809657-4.99556-5] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Rinne P, Guillamat-Prats R, Rami M, Bindila L, Ring L, Lyytikäinen LP, Raitoharju E, Oksala N, Lehtimäki T, Weber C, van der Vorst EPC, Steffens S. Palmitoylethanolamide Promotes a Proresolving Macrophage Phenotype and Attenuates Atherosclerotic Plaque Formation. Arterioscler Thromb Vasc Biol 2018;38:2562-75. [PMID: 30354245 DOI: 10.1161/ATVBAHA.118.311185] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 9.7] [Reference Citation Analysis]
4 Kim AS, Conte MS. Specialized pro-resolving lipid mediators in cardiovascular disease, diagnosis, and therapy. Advanced Drug Delivery Reviews 2020;159:170-9. [DOI: 10.1016/j.addr.2020.07.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
5 Serhan CN, Chiang N, Dalli J. New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration. Mol Aspects Med 2018;64:1-17. [PMID: 28802833 DOI: 10.1016/j.mam.2017.08.002] [Cited by in Crossref: 92] [Cited by in F6Publishing: 106] [Article Influence: 18.4] [Reference Citation Analysis]
6 Chiang N, Serhan CN. Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors. Mol Aspects Med 2017;58:114-29. [PMID: 28336292 DOI: 10.1016/j.mam.2017.03.005] [Cited by in Crossref: 138] [Cited by in F6Publishing: 134] [Article Influence: 27.6] [Reference Citation Analysis]
7 Wei M, Zhou RL, Luo T, Deng ZY, Li J. Trans triacylglycerols from dairy products and industrial hydrogenated oil exhibit different effects on the function of human umbilical vein endothelial cells via modulating phospholipase A2/arachidonic acid metabolism pathways. J Dairy Sci 2021;104:6399-414. [PMID: 33773784 DOI: 10.3168/jds.2020-19715] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Xiong J, He T, Yu Z, Yang K, Chen F, Cheng J, Shi Y, Huang Y, Qiao Y, Li H, Shen Y, Zhao J. Antiplatelet therapy for the prevention of atherosclerosis in chronic kidney disease (ALTAS-CKD) patients: study protocol for a randomized clinical trial. Trials 2021;22:37. [PMID: 33413594 DOI: 10.1186/s13063-020-04992-x] [Reference Citation Analysis]
9 Feng Z, Wang C, Yue, Jin, Meng Q, Wu J, Sun H. Kaempferol-induced GPER upregulation attenuates atherosclerosis via the PI3K/AKT/Nrf2 pathway. Pharm Biol 2021;59:1106-16. [PMID: 34403325 DOI: 10.1080/13880209.2021.1961823] [Reference Citation Analysis]
10 Artiach G, Bäck M. Omega-3 Polyunsaturated Fatty Acids and the Resolution of Inflammation: Novel Therapeutic Opportunities for Aortic Valve Stenosis? Front Cell Dev Biol 2020;8:584128. [PMID: 33304901 DOI: 10.3389/fcell.2020.584128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Engelen SE, Robinson AJB, Zurke Y, Monaco C. Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed? Nat Rev Cardiol. [DOI: 10.1038/s41569-021-00668-4] [Reference Citation Analysis]
12 Wang B, Wu L, Chen J, Dong L, Chen C, Wen Z, Hu J, Fleming I, Wang DW. Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets. Signal Transduct Target Ther 2021;6:94. [PMID: 33637672 DOI: 10.1038/s41392-020-00443-w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
13 Fredman G, MacNamara KC. Atherosclerosis is a Major Human Killer and Non-resolving Inflammation is a Prime Suspect. Cardiovasc Res 2021:cvab309. [PMID: 34609505 DOI: 10.1093/cvr/cvab309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Bäck M, Yurdagul A Jr, Tabas I, Öörni K, Kovanen PT. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nat Rev Cardiol 2019;16:389-406. [PMID: 30846875 DOI: 10.1038/s41569-019-0169-2] [Cited by in Crossref: 147] [Cited by in F6Publishing: 184] [Article Influence: 73.5] [Reference Citation Analysis]
15 Maffia P, Cirino G. Targeting inflammation to reduce cardiovascular disease risk. Br J Pharmacol 2017;174:3895-7. [PMID: 29080212 DOI: 10.1111/bph.14039] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
16 Lordan R, Tsoupras A, Zabetakis I. Platelet activation and prothrombotic mediators at the nexus of inflammation and atherosclerosis: Potential role of antiplatelet agents. Blood Rev 2021;45:100694. [PMID: 32340775 DOI: 10.1016/j.blre.2020.100694] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 10.5] [Reference Citation Analysis]
17 Artiach G, Carracedo M, Plunde O, Wheelock CE, Thul S, Sjövall P, Franco-Cereceda A, Laguna-Fernandez A, Arnardottir H, Bäck M. Omega-3 Polyunsaturated Fatty Acids Decrease Aortic Valve Disease Through the Resolvin E1 and ChemR23 Axis. Circulation 2020;142:776-89. [PMID: 32506925 DOI: 10.1161/CIRCULATIONAHA.119.041868] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
18 Schaller MS, Chen M, Colas RA, Sorrentino TA, Lazar AA, Grenon SM, Dalli J, Conte MS. Treatment With a Marine Oil Supplement Alters Lipid Mediators and Leukocyte Phenotype in Healthy Patients and Those With Peripheral Artery Disease. J Am Heart Assoc 2020;9:e016113. [PMID: 32696697 DOI: 10.1161/JAHA.120.016113] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
19 Zhao J, Geng W, Wan K, Guo K, Xi F, Xu X, Xiong X, Huang X, Liu J, Kuang X. Lipoxin A4 promotes autophagy and inhibits overactivation of macrophage inflammasome activity induced by Pg LPS. J Int Med Res 2021;49:300060520981259. [PMID: 33528285 DOI: 10.1177/0300060520981259] [Reference Citation Analysis]
20 Pirault J, Bäck M. Lipoxin and Resolvin Receptors Transducing the Resolution of Inflammation in Cardiovascular Disease. Front Pharmacol 2018;9:1273. [PMID: 30487747 DOI: 10.3389/fphar.2018.01273] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 12.8] [Reference Citation Analysis]
21 Doran AC. Inflammation Resolution: Implications for Atherosclerosis. Circ Res 2022;130:130-48. [PMID: 34995137 DOI: 10.1161/CIRCRESAHA.121.319822] [Reference Citation Analysis]
22 Heinz J, Marinello M, Fredman G. Pro-resolution therapeutics for cardiovascular diseases. Prostaglandins & Other Lipid Mediators 2017;132:12-6. [DOI: 10.1016/j.prostaglandins.2017.03.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
23 Kasikara C, Doran AC, Cai B, Tabas I. The role of non-resolving inflammation in atherosclerosis. J Clin Invest 2018;128:2713-23. [PMID: 30108191 DOI: 10.1172/JCI97950] [Cited by in Crossref: 92] [Cited by in F6Publishing: 45] [Article Influence: 23.0] [Reference Citation Analysis]
24 Chistiakov DA, Melnichenko AA, Grechko AV, Myasoedova VA, Orekhov AN. Potential of anti-inflammatory agents for treatment of atherosclerosis. Exp Mol Pathol 2018;104:114-24. [PMID: 29378168 DOI: 10.1016/j.yexmp.2018.01.008] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 10.5] [Reference Citation Analysis]
25 Shang P, Zhang Y, Ma D, Hao Y, Wang X, Xin M, Zhang Y, Zhu M, Feng J. Inflammation resolution and specialized pro-resolving lipid mediators in CNS diseases. Expert Opin Ther Targets 2019;23:967-86. [PMID: 31711309 DOI: 10.1080/14728222.2019.1691525] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
26 Satish M, Agrawal DK. Pro-resolving lipid mediators in the resolution of neointimal hyperplasia pathogenesis in atherosclerotic diseases. Expert Rev Cardiovasc Ther 2019;17:177-84. [PMID: 30582389 DOI: 10.1080/14779072.2019.1563483] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
27 Guimarães RC, Gonçalves TT, Leiria LO. Exploiting oxidized lipids and the lipid-binding GPCRs against cardiometabolic diseases. Br J Pharmacol 2021;178:531-49. [PMID: 33169375 DOI: 10.1111/bph.15321] [Reference Citation Analysis]
28 Soehnlein O, Libby P. Targeting inflammation in atherosclerosis - from experimental insights to the clinic. Nat Rev Drug Discov 2021;20:589-610. [PMID: 33976384 DOI: 10.1038/s41573-021-00198-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
29 Fredman G, Spite M. Specialized pro-resolving mediators in cardiovascular diseases. Mol Aspects Med 2017;58:65-71. [PMID: 28257820 DOI: 10.1016/j.mam.2017.02.003] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 7.6] [Reference Citation Analysis]
30 Chen Y, Zheng Y, Xin L, Zhong S, Liu A, Lai W, Liu L, Lin C, Liao C, Zeng J, Zhang L. 15-epi-lipoxin A4 inhibits TNF-α-induced tissue factor expression via the PI3K/AKT/ NF-κB axis in human umbilical vein endothelial cells. Biomedicine & Pharmacotherapy 2019;117:109099. [DOI: 10.1016/j.biopha.2019.109099] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
31 Sonnweber T, Pizzini A, Nairz M, Weiss G, Tancevski I. Arachidonic Acid Metabolites in Cardiovascular and Metabolic Diseases. Int J Mol Sci 2018;19:E3285. [PMID: 30360467 DOI: 10.3390/ijms19113285] [Cited by in Crossref: 78] [Cited by in F6Publishing: 74] [Article Influence: 19.5] [Reference Citation Analysis]
32 Wickstead ES, Karim HA, Manuel RE, Biggs CS, Getting SJ, McArthur S. Reversal of β-Amyloid-Induced Microglial Toxicity In Vitro by Activation of Fpr2/3. Oxid Med Cell Longev 2020;2020:2139192. [PMID: 32617132 DOI: 10.1155/2020/2139192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
33 Conte MS, Desai TA, Wu B, Schaller M, Werlin E. Pro-resolving lipid mediators in vascular disease. J Clin Invest 2018;128:3727-35. [PMID: 30168805 DOI: 10.1172/JCI97947] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 6.8] [Reference Citation Analysis]
34 Mai J, Liu W, Fang Y, Zhang S, Qiu Q, Yang Y, Wang X, Huang T, Zhang H, Xie Y, Lin M, Chen Y, Wang J. The atheroprotective role of lipoxin A4 prevents oxLDL-induced apoptotic signaling in macrophages via JNK pathway. Atherosclerosis 2018;278:259-68. [PMID: 30340110 DOI: 10.1016/j.atherosclerosis.2018.09.025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
35 Petri MH, Thul S, Andonova T, Lindquist-Liljeqvist M, Jin H, Skenteris NT, Arnardottir H, Maegdefessel L, Caidahl K, Perretti M, Roy J, Bäck M. Resolution of Inflammation Through the Lipoxin and ALX/FPR2 Receptor Pathway Protects Against Abdominal Aortic Aneurysms. JACC Basic Transl Sci 2018;3:719-27. [PMID: 30623131 DOI: 10.1016/j.jacbts.2018.08.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
36 Xu F, Zhang J, Zhou X, Hao H. Lipoxin A4 and its analog attenuate high fat diet-induced atherosclerosis via Keap1/Nrf2 pathway. Exp Cell Res 2022;412:113025. [PMID: 35026282 DOI: 10.1016/j.yexcr.2022.113025] [Reference Citation Analysis]
37 Kraft JD, Blomgran R, Bergström I, Soták M, Clark M, Rani A, Rajan MR, Dalli J, Nyström S, Quiding‐järbrink M, Bromberg J, Skoog P, Börgeson E. Lipoxins modulate neutrophil oxidative burst, integrin expression and lymphatic transmigration differentially in human health and atherosclerosis. The FASEB Journal 2022;36. [DOI: 10.1096/fj.202101219rr] [Reference Citation Analysis]
38 Imig JD. Eicosanoid blood vessel regulation in physiological and pathological states. Clin Sci (Lond) 2020;134:2707-27. [PMID: 33095237 DOI: 10.1042/CS20191209] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
39 Carracedo M, Artiach G, Arnardottir H, Bäck M. The resolution of inflammation through omega-3 fatty acids in atherosclerosis, intimal hyperplasia, and vascular calcification. Semin Immunopathol 2019;41:757-66. [PMID: 31696250 DOI: 10.1007/s00281-019-00767-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 7.7] [Reference Citation Analysis]
40 Brennan E, Mohan M, Andrews D, Bose M, Kantharidis P. Specialized pro-resolving mediators in diabetes: novel therapeutic strategies. Clinical Science 2019;133:2121-41. [DOI: 10.1042/cs20190067] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
41 Pascoal LB, Palma BB, Chaim FHM, de Castro MM, Damázio TA, Franceschini APMF, Milanski M, Velloso LA, Leal RF. New translational and experimental insights into the role of pro-resolving lipid mediators in inflammatory bowel disease. World J Exp Med 2022; 12(1): 1-15 [DOI: 10.5493/wjem.v12.i1.1] [Reference Citation Analysis]
42 Lordan R, Redfern S, Tsoupras A, Zabetakis I. Inflammation and cardiovascular disease: are marine phospholipids the answer? Food Funct 2020;11:2861-85. [DOI: 10.1039/c9fo01742a] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 8.5] [Reference Citation Analysis]
43 Gila-Diaz A, Carrillo GH, Singh P, Ramiro-Cortijo D. Specialized Pro-Resolving Lipid Mediators in Neonatal Cardiovascular Physiology and Diseases. Antioxidants (Basel) 2021;10:933. [PMID: 34201378 DOI: 10.3390/antiox10060933] [Reference Citation Analysis]
44 Bäck M. Omega-3 fatty acids in atherosclerosis and coronary artery disease. Future Sci OA 2017;3:FSO236. [PMID: 29134121 DOI: 10.4155/fsoa-2017-0067] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
45 Wang D, Yang Y, Lei Y, Tzvetkov NT, Liu X, Yeung AWK, Xu S, Atanasov AG. Targeting Foam Cell Formation in Atherosclerosis: Therapeutic Potential of Natural Products. Pharmacol Rev 2019;71:596-670. [PMID: 31554644 DOI: 10.1124/pr.118.017178] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 12.0] [Reference Citation Analysis]
46 Carracedo M, Artiach G, Witasp A, Clària J, Carlström M, Laguna-fernandez A, Stenvinkel P, Bäck M. The G-protein coupled receptor ChemR23 determines smooth muscle cell phenotypic switching to enhance high phosphate-induced vascular calcification. Cardiovascular Research 2019;115:1557-66. [DOI: 10.1093/cvr/cvy316] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
47 Caso VM, Manzo V, Pecchillo Cimmino T, Conti V, Caso P, Esposito G, Russo V, Filippelli A, Ammendola R, Cattaneo F. Regulation of Inflammation and Oxidative Stress by Formyl Peptide Receptors in Cardiovascular Disease Progression. Life (Basel) 2021;11:243. [PMID: 33804219 DOI: 10.3390/life11030243] [Reference Citation Analysis]
48 Chuong P, Wysoczynski M, Hellmann J. Do Changes in Innate Immunity Underlie the Cardiovascular Benefits of Exercise? Front Cardiovasc Med 2019;6:70. [PMID: 31192231 DOI: 10.3389/fcvm.2019.00070] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
49 Tabas I, Lichtman AH. Monocyte-Macrophages and T Cells in Atherosclerosis. Immunity 2017;47:621-34. [PMID: 29045897 DOI: 10.1016/j.immuni.2017.09.008] [Cited by in Crossref: 237] [Cited by in F6Publishing: 230] [Article Influence: 47.4] [Reference Citation Analysis]
50 Fredman G. Can Inflammation-Resolution Provide Clues to Treat Patients According to Their Plaque Phenotype? Front Pharmacol 2019;10:205. [PMID: 30899222 DOI: 10.3389/fphar.2019.00205] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
51 Bardin M, Pawelzik SC, Lagrange J, Mahdi A, Arnardottir H, Regnault V, Fève B, Lacolley P, Michel JB, Mercier N, Bäck M. The resolvin D2 - GPR18 axis is expressed in human coronary atherosclerosis and transduces atheroprotection in apolipoprotein E deficient mice. Biochem Pharmacol 2022;:115075. [PMID: 35525326 DOI: 10.1016/j.bcp.2022.115075] [Reference Citation Analysis]
52 Wasserman AH, Venkatesan M, Aguirre A. Bioactive Lipid Signaling in Cardiovascular Disease, Development, and Regeneration. Cells 2020;9:E1391. [PMID: 32503253 DOI: 10.3390/cells9061391] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
53 Petri MH, Laguna-Fernandez A, Arnardottir H, Wheelock CE, Perretti M, Hansson GK, Bäck M. Aspirin-triggered lipoxin A4 inhibits atherosclerosis progression in apolipoprotein E-/- mice. Br J Pharmacol 2017;174:4043-54. [PMID: 28071789 DOI: 10.1111/bph.13707] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 10.4] [Reference Citation Analysis]
54 Dubé L, Spahis S, Lachaîne K, Lemieux A, Monhem H, Poulin S, Randoll C, Travaillaud E, Ould-chikh N, Marcil V, Delvin E, Levy E. SPECIALIZED PRO-RESOLVING MEDIATORS DERIVED FROM N-3 POLYUNSATURATED FATTY ACIDS: ROLE IN METABOLIC SYNDROME AND RELATED COMPLICATIONS. Antioxidants & Redox Signaling. [DOI: 10.1089/ars.2021.0156] [Reference Citation Analysis]
55 Laguna-Fernandez A, Checa A, Carracedo M, Artiach G, Petri MH, Baumgartner R, Forteza MJ, Jiang X, Andonova T, Walker ME, Dalli J, Arnardottir H, Gisterå A, Thul S, Wheelock CE, Paulsson-Berne G, Ketelhuth DFJ, Hansson GK, Bäck M. ERV1/ChemR23 Signaling Protects Against Atherosclerosis by Modifying Oxidized Low-Density Lipoprotein Uptake and Phagocytosis in Macrophages. Circulation 2018;138:1693-705. [PMID: 29739755 DOI: 10.1161/CIRCULATIONAHA.117.032801] [Cited by in Crossref: 59] [Cited by in F6Publishing: 36] [Article Influence: 19.7] [Reference Citation Analysis]
56 Su X, Peng D. The exchangeable apolipoproteins in lipid metabolism and obesity. Clin Chim Acta 2020;503:128-35. [PMID: 31981585 DOI: 10.1016/j.cca.2020.01.015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
57 Jaén RI, Sánchez-García S, Fernández-Velasco M, Boscá L, Prieto P. Resolution-Based Therapies: The Potential of Lipoxins to Treat Human Diseases. Front Immunol 2021;12:658840. [PMID: 33968061 DOI: 10.3389/fimmu.2021.658840] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]